Postmenopausal osteoporosis

Treatment of postmenopausal osteoporosis with Preotact®

Osteoporosis is a bone disease that is most common in women after menopause this is also known as postmenopausal osteoporosis. Postmenopausal osteoporosis is caused by estrogen deficiency following menopause that results in a rapid reduction of bone mineral density. There are often no symptoms of postmenopausal osteoporosis before the first bone fracture occurs.

Preotact® is a full-length parathyroid hormone (PTH) therapy that can reduce the risk of bone fracture for postmenopausal osteoporosis patients. Studies have demonstrated that Preotact® injections can increase bone mineral density and mechanical strength of postmenopausal osteoporosis patients.

Log in to learn more about treatment of postmenopausal osteoporosis 

Nycomed

Nycomed is a European pharmaceutical company that has over 20 years’ experience of working with osteoporosis. Nycomed operates throughout Europe and in fast-growing markets in Latin America, Russia/CIS and Asia-Pacific.

Nycomed provides medicines and products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. Offering a broad portfolio of products in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management.